Table 1.

HER2 and TOP2A Gene Amplification Associations

Genotype	Patient Data		Disease-Free Survival			Overall Survival
	No.	%	HR	95% CI	P	HR	95% CI	P
HER2/CEP17	1,483
≥ 2.0	279	19	1.07	0.83 to 1.37	.62	1.14	0.85 to 1.52	.39
≥ 4.0	149	10	1.38	1.03 to 1.85	.033	1.45	1.04 to 2.03	.03
≥ 6.0	51	3.4	1.76	1.14 to 2.73	.01	1.58	0.95 to 2.63	.08
≥ 8.0	16	1.1	2.48	1.27 to 4.82	.008	1.75	0.72 to 4.28	.22
≤ 0.70 or ≥ 2.0	303	20	1.11	0.87 to 1.42	.39	1.21	0.91 to 1.60	.19
TOP2A/CEP17
≥ 2.0	65	4.0	0.98	0.60 to 1.59	.92	1.10	0.64 to 1.89	.72
≥ 4.0	13	0.8	0.52	0.13 to 2.08	.35	0.77	0.19 to 3.11	.72
≥ 6.0	4	0.3	NE	NE	NE	NE	NE	NE
≤ 0.70 or ≥ 2.0	153	9.4	1.05	0.77 to 1.45	.75	1.24	0.87 to 1.78	.23
TOP2A copy
≥ 4.0	195	12	1.07	0.80 to 1.44	.64	1.10	0.78 to 1.56	.58
≥ 6.0	48	3.0	0.70	0.38 to 1.32	.27	0.87	0.45 to 1.69	.68
HER2/CEP17 > 4.0 subset	140
TOP2A/CEP17
≥ 2.0	33	24	0.79	0.40 to 1.59	.51	0.81	0.37 to 1.78	.61
≥ 4.0	7	5	0.62	0.15 to 2.62	.51	0.82	0.19 to 3.57	.79
≤ 0.70 or ≥ 2.0	51	36	0.78	0.43 to 1.41	.41	0.72	0.36 to 1.43	.34

NOTE. Analysis was adjusted for hormone receptor status, tumor size, number of positive nodes, menopausal status, and randomized treatment assignment.

Abbreviations: HR, hazard ratio; NE, not estimable.